I must admit I never envisioned these levels .06 to .08.
I must admit I never envisioned these levels .06 to .08. First and foremost I believe the action on Wednesday from .115 to .0669 was done intentionally with malice. As we all know it came out of 1 mm csti approx 7m of the 8.8m sold. Frankly as bad as it was and indeed it was SCRC was able to handle 9m shares of trading and essentially finish at .07 cents. If someone would have said to me that we were going to trade 9m shares frankly although bad at .07 it could have been far worse and much lower. There is no doubt in my mind it was 1 individual who wanted to hurt the company. Well from .11 to .0669 we have already recoverd 50% on what we lost Wednesday. Now oddly enough this has brought more eyes on SCRC mostly scalpers/traders which is fine. I believe most will scalp 10% to 25% and be gone, however a few may look at what they own and decide to actually invest a few shares in SCRC. If we are able to recover to .10 cents in the next several weeks then this move down was worth it because it will bring in more awareness.
There is no question the termination with CVS hurt business and I personally did not see this coming nor did anyone. CVS is a big part of the market roughly 30%. To shed a blind eye to this would be a mistake, however the company can do other things on the expense side to soften the blow. Also if and when a new pharmacy is commenced we will move from 7 states to approx 40 states is my understanding. It will take time to fully ramp up at the new site when it takes place to train a pharmacist and learn the business.remember when we started on at Main Ave it took several months to truly ramp up. This will be no different when it comes and I have strong belief in Bob and his team that we will do very well in the 2nd half of the year. I have no idea what the #s will be but with the additional 33 states and lets say we start that in q3 that will help us out tremendously.
I would like to state that SCRC is a penny stock and often seems to be under a microscope. We should be looking at the macro picture when investing at SCRC. I have no comment on q4 as thats in the rear view mirror now and we all will look at the 10k when its completed and then make comments. The good news that q1 is profitable not an easy task for a penny stock. Yes its probably lower than most would like but I am happy it's in the black. Whatever took place in q4 it seems we have straightened out some issues. The company still expects to be profitable this year and there are things further out that can help us enormously. Rapimeds/dispensing program can be a big lift. I will not put a time-line on either as I want to see how the pilot program takes place at the dispensing program. A new pharmacy can be very enormous especially with the additional 33 states and my expectation is 90 to 120 days out for any meaningful business. Again I have no ideas what the #s will be as I will not put the cart before the horse.
We will survive this latest hit as we are profitable in q1 and will still have cash as well as the 4m L.O.C. Congrats to all the CORE for digging in during this most trying time and Thank you for all your support as well. I know many of the core that bought in at .07 to .09 and I hope your rewarded for your efforts. I see that the "CORE" is recognized now for having 40m shares which is a pretty significant part of the float of approx 85m. We have survived 39 notes, Having no $$$$ for almost 2 years, Ironridge approx 12m shares free trading, losing CVS, and a huge seller on Wednesday. Not only will we survive this there will be a time that we will thrive again as a company as well as a stock. The dream is intact for all and I appreciate all your efforts in bringing the very best to SCRC.
SHOCK AND AWE COMING TO A LOCAL THEATRE
ScripsAmerica Inc (SCRC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...
Continue Reading
In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...
Continue Reading
The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...
Continue Reading
Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...
Continue Reading
Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...
Continue Reading
A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...
Continue Reading
The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...
Continue Reading
Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...
Continue Reading
Top 5 Most Recently Viewed Articles
Homestyle Direct Expands Access to Medically Tailored Meals Delivering Nutritious Meals Across Five Counties Homestyle Direct is thrilled to announce its expansion into several new markets in California. This significant development supports the company's commitment to delivering nutritious, medically tailored meal options to eligible Medi-Cal members. With this...
Continue Reading
Introduction to the Lumina+ MOCVD System Veeco Instruments Inc. (NASDAQ: VECO), a leading manufacturer of semiconductor process equipment, has launched its innovative Lumina+ metal-organic chemical vapor deposition (MOCVD) system. This exciting announcement coincides with the receipt of a multi-tool order from Rocket Lab Corporation (NASDAQ: RKLB), aimed at boosting...
Continue Reading
A Stunning Estate Awaits by Lake Winnipesaukee Introducing an extraordinary estate located at 68 & 73 Sewall Road, where luxury intertwines with a rich legacy. This incredible waterfront property is now available, offering an exceptional lifestyle for those seeking upscale lakeside living. About the Property Covering over 4.5 acres, this estate boasts 247 feet of pristine...
Continue Reading
Investors Have a Crucial Opportunity with WEBTOON Entertainment Inc. In a notable turn of events, investors in WEBTOON Entertainment Inc. are now facing a chance to lead a class action lawsuit against the company. The Schall Law Firm, a firm known for its work in protecting shareholder rights, has begun legal proceedings because of alleged violations of federal securities...
Continue Reading
Raft and N3bula Systems Unite for Enhanced Defense Solutions In a groundbreaking merger, Raft has joined forces with N3bula Systems to revolutionize defense technology. This strategic alliance focuses on creating a cohesive AI and data infrastructure pivotal for modern military operations. The newly combined entity is set to propel defense modernization, optimizing how...
Continue Reading